Premium
Use of rhodamine 123 in the treatment of the pollard iii rat prostate adenocarcinoma
Author(s) -
Arcadi John A.
Publication year - 1990
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930440209
Subject(s) - medicine , adenocarcinoma , rhodamine 123 , prostate , rhodamine , prostate adenocarcinoma , urology , pathology , cancer , biology , drug resistance , fluorescence , physics , quantum mechanics , multiple drug resistance , microbiology and biotechnology
Significant destruction of the Pollard III rat prostate adenocarcinoma was achieved by treatment with rhodamine 123 at a dosage of 15 mg/kg every other day for 33 to 38 days. Injection of tumor remnants into untreated animals produced no tumor regrowth. Our data have demonstrated rhodamine 123 to be a significant drug for the management of the very aggressive Pollard III tumor.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom